Study guide

Glaucoma medicines, SLT and MIGS

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Glaucoma medicines, SLT and MIGS

Key Takeaways Explain This Topic AI

Choose pressure medication with systemic contraindications, surface tolerance and adherence in mind.

LiGHT supports initial SLT in suitable treatment-naive OHT and open-angle glaucoma, with individual response variation.

Trabecular procedures and bleb-forming microimplants have different drainage routes and postoperative risks.

Last updated: October 2026

The contemporary management of glaucoma spans a sophisticated continuum ranging from targeted topical pharmacotherapy and biological laser trabeculoplasty to ab-interno micro-invasive implants and guarded incisional filtration surgery. Selecting the optimal intervention requires balancing efficacy, long-term diurnal stability, safety profiles, patient adherence, and individual lifestyle factors.

Medical Hypotensive Pharmacotherapy

Topical ocular hypotensive medications lower intraocular pressure either by suppressing aqueous humor secretion from the non-pigmented ciliary epithelium or by accelerating aqueous outflow through the conventional (trabecular) or unconventional (uveoscleral) pathways.

1. Prostaglandin Analogues (PGAs)

Active Compounds : Latanoprost 0.005%, Bimatoprost 0.01% / 0.03% (prostamide), Travoprost 0.004%, and Tafluprost 0.0015% (preservative-free formulation).

Mechanism of Action : Selective agonists of the prostanoid FP receptor located on ciliary muscle cells and scleral fibroblasts. Activation stimulates the transcription and upregulation of Matrix Metalloproteinases (MMPs: MMP-1, MMP-3, MMP-9) . These enzymes degrade and remodel extracellular collagen between ciliary muscle bundles, markedly reducing resistance along the uveoscleral (unconventional) outflow pathway .

Selection : Prostaglandin analogues are common initial medicines, often once daily; effect, dosing and suitability depend on drug, label and patient factors.

Adverse Effects :

Ocular : Conjunctival hyperemia (bimatoprost > > > travoprost > > > latanoprost); irreversible hyperpigmentation of the iris stroma (melanogenesis stimulated in existing melanocytes, not cellular hyperplasia; common in hazel/green-brown irides); eyelash hypertrichosis (hypertrophy, lengthening, thickening, and darkening of cilia); Prostaglandin-Associated Periorbitopathy (PAP) characterized by orbital fat atrophy, deepening of the upper eyelid sulcus, enophthalmos, and mild ptosis; cystoid macular edema (CME, especially in pseudophakic eyes with posterior capsule tears); anterior uveitis; and reactivation of latent herpes simplex keratitis (HSV) .

2. Beta-Adrenergic Antagonists (Beta-Blockers)

Active Compounds : Timolol maleate 0.25% / 0.5% (non-selective β 1 \beta_1 β 1 ​ and β 2 \beta_2 β 2 ​ ); Betaxolol 0.25% suspension / 0.5% solution (cardioselective β 1 \beta_1 β 1 ​ ); Carteolol 1% (non-selective with intrinsic sympathomimetic activity [ISA]).

Mechanism of Action : Competitive antagonism of β 2 \beta_2 β 2 ​ -receptors on the non-pigmented ciliary epithelium , inhibiting Gs-protein activation of adenylyl cyclase, reducing cyclic AMP (cAMP), and decreasing aqueous humor secretion by 20% to 25% . Dosed once daily in the morning or twice daily.

Nocturnal effect: Beta-blockers often lower nocturnal pressure less than daytime pressure because aqueous production falls during sleep. “Zero effect at night” is too absolute.

Systemic Contraindications & Side Effects :

Respiratory : Severe bronchospasm and respiratory failure. ABSOLUTE CONTRAINDICATION in bronchial asthma and severe COPD .

Cardiovascular : Sinus bradycardia ( < 50 <50 < 50 bpm), second-degree or third-degree atrioventricular (AV) heart block, cardiogenic shock, and overt congestive heart failure.

Metabolic / Neuropsychiatric : Masking of adrenergic warning signs of hypoglycemia (tachycardia, tremor) in insulin-dependent diabetics; fatigue, depression, sleep disturbances, exercise intolerance, and erectile dysfunction.

Betaxolol : Cardioselectivity ( β 1 \beta_1 β 1 ​ ) provides a safer pulmonary profile, but hypotensive efficacy is lower (~15–20% reduction).

3. Alpha-2 Adrenergic Agonists

Active Compounds : Brimonidine tartrate 0.1% / 0.15% (with Purite preservative) / 0.2%; Apraclonidine 0.5% / 1.0% (used peri-procedurally to blunt post-laser IOP spikes).

Mechanism of Action : Highly selective α 2 \alpha_2 α 2 ​ -adrenoreceptor agonist (selectivity α 2 : α 1 \alpha_2:\alpha_1 α 2 ​ : α 1 ​ is 1000:1). Acts via a dual mechanism : 1) decreases aqueous humor secretion through Gi-protein inhibition of adenylyl cyclase; and 2) increases uveoscleral outflow via stimulation of endogenous prostaglandin synthesis. Delivers 20% to 25% IOP reduction ; dosed twice or three times daily.

Adverse Effects & Black Box Pediatric Warning :

Local : High rate of allergic contact blepharoconjunctivitis (follicular conjunctivitis, erythema in 15–20% of chronic users).

Systemic : Xerostomia (dry mouth), fatigue, drowsiness, headache, hypotension, and bradycardia. Contraindicated with monoamine oxidase (MAO) inhibitors and tricyclic antidepressants.

FATAL PEDIATRIC WARNING : Strictly contraindicated in neonates, infants, and children under 2 years of age . Brimonidine readily crosses the immature blood-brain barrier, stimulating central α 2 \alpha_2 α 2 ​ -receptors to produce life-threatening central nervous system depression, profound somnolence, hypothermia, severe bradycardia, hypotension, and fatal respiratory arrest/apnea .

4. Carbonic Anhydrase Inhibitors (CAIs)

Active Compounds : Topical: Dorzolamide hydrochloride 2%, Brinzolamide 1% (suspension, pH 7.5, causing significantly less stinging than dorzolamide, pH 5.6). Systemic: Acetazolamide (Diamox, oral/IV), Methazolamide.

Mechanism of Action : Reversibly inhibits carbonic anhydrase II in the non-pigmented ciliary epithelium, slowing the conversion of C O 2 CO_2 C O 2 ​ and H 2 O H_2O H 2 ​ O into bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ​ ). This impairs active sodium and water transport into the posterior chamber, suppressing aqueous production by 15% to 20% (topical) or 30% to 40% (systemic) .

Adverse Effects :

Topical : Bitter metallic dysgeusia, superficial punctate keratitis, stinging, and irreversible corneal endothelial decompensation in compromised corneas (e.g., Fuchs endothelial dystrophy).

Systemic : Paresthesias (tingling of extremities), metabolic acidosis, hypokalemia, malaise, anorexia, gastrointestinal distress, calcium phosphate nephrolithiasis, idiosyncratic acute transient myopia/choroidal effusion, and rare fatal idiosyncratic aplastic anemia, agranulocytosis, and Stevens-Johnson syndrome . Caution in sulfa allergy.

5. Rho Kinase (ROCK) Inhibitors

Active Compounds : Netarsudil 0.02% (Rhopressa), Ripasudil 0.4%.

Mechanism of Action : Inhibits Rho-associated protein kinase (ROCK-1 and ROCK-2), promoting actin stress fiber disassembly, focal adhesion breakdown, and cellular relaxation within the trabecular meshwork and Schlemm canal endothelium. This directly lowers conventional trabecular outflow resistance . Netarsudil secondarily lowers episcleral venous pressure (EVP) and inhibits the norepinephrine transporter (NET).

Efficacy and adverse effects: Netarsudil response varies with baseline pressure and the patient. Hyperaemia, cornea verticillata and conjunctival haemorrhage can occur; reticular epithelial corneal oedema is also a recognized adverse effect. Use the locally authorized formulation and product information; do not promise a fixed 4–5 mmHg fall or assume every corneal change is harmless.

Laser Trabeculoplasty and the LiGHT Trial

Selective laser trabeculoplasty (SLT) targets pigmented trabecular cells with a short-pulsed 532-nm laser and stimulates an outflow response. It can be offered as initial therapy in suitable open-angle glaucoma or ocular hypertension, or as an adjunct. Discuss transient inflammation, pressure spikes, incomplete response and later need for medication or repeat treatment.

LiGHT compared an initial SLT strategy with drops in treatment-naive OHT/open-angle glaucoma. At three years, 74.2% of patients in the SLT group remained drop-free at target. The six-year report in Ophthalmology (2023) found 69.8% of SLT-group eyes remained at target without medical or surgical treatment; progression occurred in 19.6% versus 26.8% in the initial-drops group. Do not mix patient and eye denominators or attribute differences in cataract surgery to proven preservative causation.

SLT can be repeated in selected eyes, with variable response. Argon laser trabeculoplasty produces more thermal structural change; repeat options and safety differ. Check the angle, pigment, inflammation, baseline pressure and follow-up capacity before laser. See the six-year trial report .

Micro-Invasive Glaucoma Surgery (MIGS)

MIGS terminology varies. Many trabecular procedures use an ab-interno approach and preserve conjunctiva, but bleb-forming microstents and ab-externo microshunts have different anatomy and postoperative risks. Describe the actual route, pressure goal and evidence rather than applying a universal five-item definition to every small implant.

Outflow Pathway Platform Examples Surgical Mechanism Indications & Clinical Profile

Trabecular Meshwork Bypass / Schlemm Canal iStent inject / inject W Two titanium micro-stents preloaded on an automated inserter, placed ab-interno into Schlemm canal 2-3 clock hours apart Mild-to-moderate POAG; often combined with phacoemulsification; high safety; modest pressure reduction

Schlemm Canal Scaffolding Hydrus Microstent 8-mm flexible nitinol scaffold inserted into Schlemm canal, bypassing the trabecular meshwork through its inlet and scaffolding the canal across 90 ∘ 90^\circ 9 0 ∘ (3 clock hours) Mild-to-moderate POAG; accesses multiple collector channels; superior medication-free rates (HORIZON trial)

Trabecular Excision (Ab-Interno Goniotomy) Kahook Dual Blade (KDB) / GATT Excises a strip of diseased juxtacanalicular meshwork (KDB) or 360 ∘ 360^\circ 36 0 ∘ catheter-assisted suture unroofing (GATT) Moderate POAG, juvenile open-angle glaucoma, secondary glaucomas; eliminates juxtacanalicular resistance

Suprachoroidal Shunt MINIject / (CyPass withdrawn) Flexible porous biocompatible silicone implant placed ab-interno into the supraciliary/suprachoroidal space Moderate OAG; harnesses negative suprachoroidal pressure; CyPass recalled due to endothelial cell loss

Subconjunctival Filtration Bleb XEN 45 Gel Stent 6-mm porcine cross-linked gelatin tube inserted ab-interno into subconjunctival space; calibrated internal lumen ( 45 μ m 45\ \mu\text{m} 45 μ m ) Moderate-to-severe refractory glaucoma; creates filtration bleb; requires Mitomycin C (MMC) to prevent subconjunctival scarring

Subconjunctival Microshunt PreserFlo MicroShunt 8.5-mm SIBS polymer tube placed ab-externo into anterior chamber, draining into posterior sub-Tenon pocket Advanced OAG; small lumen limits flow but does not eliminate hypotony; requires intraoperative MMC application